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ABSTRACT 
Objective: A liquid chromatography-tandem mass spectrophotometric (LC-MS/MS) method was developed for quantification of canagliflozin in 
rabbit plasma employing Liquid-Liquid extraction technique.  
Methods: Chromatographic separation was achieved on Inertsil ODS 5 µm C18, 50×4.60 mm with 30:70 v/v of 0.01M ammonium acetate: methanol 
as an isocratic mobile phase with a flow rate of 0.8 ml/min. The developed LC-MS method was applied to assess Cmax, t1/2, AUC0-t, and AUC0-inf of 
canagliflozin tablet after oral administration in healthy rabbits. 
Results: The developed method was linear over working range of 5ng/ml to 600ng/ml with a coefficient of correction (r2) = 0.999. The % recovery 
of the method was found to be 102.05%. The mean intraday and inter-day precision of the method was found to be 0.77 to 3.72%. The Canagliflozin 
showed Tmax of 1.58±0.2 and mean Cmax, AUC0→t and AUC0→α for Test formulation is 272±13.24, 2571.20±251and 2777.43±276 respectively. 
Conclusion: The developed method can be applied for routine analysis for quality control and the established LLOQ is sufficiently low to conduct a 
pharmacokinetic study with any marketing formulation of Canagliflozin in healthy rabbits. 
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Canagliflozin, an orally active inhibitor of sodium glucose co-
transporter 2 (SGLT2), is currently in development for the treatment 
of patients with type 2 diabetes mellitus [1-2]. Inhibition of SGLT2 
causes inhibition of glucose reabsorption in renal proximal tubular 
cells, thereby reducing the renal threshold for glucose (RTG) [3-4]. 
As per the Literature Survey, it is revealed that the Ultraviolet 
spectroscopy (UV), High-Performance Liquid Chromatography 
(HPLC) and High-Performance thin layer Chromatography (HPTLC) 
methods were reported for degradation studies and to estimate the 
canagliflozin from bulk and Pharmaceutical dosage forms [5-10]. 
Ultra High Performance/liquid Chromatography-Mass Spectroscopy 
(UHPLC-MS and LC-MS/MS) methods were reported for 
quantification of the drug in biological fluids like human and rat 
plasma [11, 12]. To best of our knowledge, no published LC-MS/MS-
based methods for the pharmacokinetic study of canagliflozin in 
healthy rabbits. Therefore a liquid chromatography-tandem mass 
spectrophotometric (LC–MS/MS) method was developed, validated 
and applied for quantification of canagliflozin in rabbit plasma 
employing liquid-liquid extraction (LLE) technique. The established 
LLOQ is sufficiently low to conduct a pharmacokinetic study with 
any marketing formulation of canagliflozin in human volunteers. 
MATERIALS AND METHODS 
Apparatus and software 
The HPLC system with an autosampler was a shimadzu LC-20ADvp, 
shimadzu, japan, coupled with applied bio system sciex, MDS Sciex, 
Canada, API 4000 tandem mass spectrometer. The autosampler was 
SIL-HTC from shimadzu, Japan. The solvent delivery module was LC-
20AD from shimadzu, Japan. The chromatographic integration was 
performed by analyst software, version: 1.4.2; applied bio systems. 
Chemicals and reagents 
Canagliflozin and empagliflozin (IS) were obtained on request from 
MSN Life Sciences Pvt. Ltd. Hyderabad and Mylon laboratories, 
Hyderabad respectively, formic acid were procured from Merck 
Specialities Pvt. Ltd, Mumbai, India. Water used was collected from 
water purification systems (Milli Q, Milli Pore, USA) installed in the 
laboratory. Methanol and acetonitrile were of HPLC grade and were 
supplied by J. T. Baker, USA. Hyderabad. The plasma was obtained 
from rabit blood by freeze centrifugation. The study was approved 
by institutional ethical committee no: VCP/IAEC/2016-48. 
Calibration standard solutions 
Stock solutions of canagliflozin and empagliflozin internal standard 
(IS) were prepared in methanol. Further dilutions were carried out 
in 70 % methanol. Calibration standards of eight concentration 
levels were prepared freshly by spiking drug-free plasma with 
canagliflozin stock solution to give the concentrations of 5.00, 10.00, 
20.00, 40.0, 100, 200, 400 and 600ng/ml. 
Quality control standards 
Lowest quality control standards, median quality control standards and 
highest quality control standards were prepared by spiking drug-free 
plasma with canagliflozin to give a solution containing 10, 300 and 500 
ng/ml respectively. They were stored at-20 °C till the time analyzed. 
Chromatographic conditions 
Chromatographic separation was performed on inertsil ODS 5 µm 
C18, 50×4.60 mm with 30:70 v/v of 0.01M ammonium acetate: 
methanol as an isocratic mobile phase with a flow rate of 0.8 
ml/min. Injection volume was 5μl. Total analysis time of single 
injection was 2.00 min. Column oven temperature and autosampler 
temperature was set to 40 °C and 5 °C, respectively.  
Mass spectrometric conditions 
The LC eluent was split (75%), and approximately 0.25 ml/min was 
introduced and quantitation was achieved with MS/MS detection in 
negative ion mode for the analytes and IS using a MDS Sciex API-
4000 mass spectrometer (Foster City, CA, USA) equipped with 
Turboion spray interface at 400 °C. The ion spray voltage was set at 
5500 V. The source parameters viz., the nebulizer gas, curtain gas, 
CAD gas were set at 8, 10 and 6 psi, respectively. The compound 
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parameters viz. the declustering potential (DP), collision energy 
(CE), entrance potential (EP) and collision cell exit potential (CXP) 
for canagliflozin and canagliflozin-D3 were similar and are 18, 10, 
10, 10 V. A turbo ion spray interface (TIS) operated in positive 
ionization mode was used for the detection. Detection of the ions 
was carried out in the multiple-reaction monitoring mode (MRM), by 
monitoring the transition pairs of m transitions of m/z 462.1→267.0 
for canagliflozin, and m/z 451.2 →71.0 for empagliflozin. 
Quadrupoles Q1 and Q3 were set on the unit resolution. 
Study design  
Six male albino rabbits (Weighing about 2.5 kg) procured by vijaya 
college of pharmacy which was obtained from the approved vendor. 
The rabbits selected for the study was approved by institutional 
ethical committee no: VCP/IAEC/2016-48. The age of the rabbits was 
8-12 w and had no medication for two weeks prior to the study. 
Twelve hours before drug administration, food was withdrawn from 
the rabbits until 24 hr post-dosing, while, water was available for 
rabbits throughout the study. The tablet with the dose of 13 mg based 
on the animal surface area was administered to rabbits. T-Blood 
samples (0.6 ml) were withdrawn from the marginal ear vein before 
dosing (zero time) and at time intervals of 0.15, 0.25,0.5 0.75, 1,1.25, 
1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 20 and 24 h after administration. For 
each animal, the total number of blood samples drawn during the 
study was 18. EDTA disodium salt was used as an anticoagulant. 
Plasma was separated by centrifugation at 5000 rpm for 10 min and 
the resulting plasma sample from each blood sample was divided into 
two aliquots and stored in suitably labelled polypropylene tubes at 20 
°C until used. All the plasma samples were analysed under the 
construction of standard calibration curve of canagliflozin in rabbit’s 
plasma. The canagliflozin concentrations in the rabbit plasma samples 
were calculated using the calibration curve, obtained after linear 
regression of the peak area ratio (canagliflozin/empagliflozin) versus 
the concentration of canagliflozin. 
Sample preparation method 
To 250 µl of plasma, 50 µl of empagliflozin (50ng/ml) was added 
and vertexed. The drug was extracted with 3 ml of TBME (tertiary 
butyl methyl ether) followed by centrifugation at 2000 rpm/min on 
a cooling centrifuge for 15 min at 4 °C. The organic phase was 
withdrawn and dried using lyophiliser. To the residue, 250 µl of 
mobile phase was added and inject by using HPLC-ESI-MS/MS.  
Pharmacokinetic analysis  
Single dosage pharmacokinetic parameters were calculated using PK 
Solver tool from plasma drug concentration-time data by non-
compartmental methods. The maximum plasma concentration (Cmax) 
and time to maximum plasma concentration (Tmax) were obtained 
directly from the observed concentration-time profiles. The linear 
trapezoidal rule was used to estimate the area under the plasma 
concentration versus time curve (AUC) from 0 to the last measurable 
concentration (AUC 0-t). The area under the plasma concentration 
versus time curve from 0 to infinity (AUC 0-∞) was calculated as 
AUC 0-t+Ct/ke, where Ct was the last measurable concentration. Ke 
was the elimination rate constant. The terminal elimination half-life 
(t1/2) was calculated as 0.693/Ke. 
Validation 
Specificity 
A solution containing 4.0ng/ml was injected on to the column under 
optimized chromatographic conditions to show the separation of 
canagliflozin from impurities and plasma. The specificity of the 
method was checked for the interference from plasma. 
Linearity 
Spiked concentrations were plotted against peak area ratios of 
canagliflozin to the internal standard and the best fit line was 
calculated. Wide range calibration was determined by solutions 
containing 5ng/ml to 600ng/ml. 
Recovery 
The % mean recoveries were determined by measuring the responses 
of the extracted plasma Quality control samples at HQC, MQC and LQC 
against unextracted Quality control samples at HQC, MQC and LQC. 
Precision and accuracy 
Intraday precision and accuracy was determined by analyzing 
quality control standards (10, 300and 500ng/ml) and LLOQ Quality 
control standard (4.00 ng/ml) five times a day randomly, interday 
precision and accuracy was determined from the analysis of each 
quality control standards (10, 300and 500ng/ml) and LLOQ quality 
control standards (4.00 ng/ml) once on each of five different days. 
Matrix effect 
The matrix effect for the intended method was assessed by using 
chromatographically screened human plasma. Concentrations 
equivalent to LQC and HQC of canagliflozin were prepared with six 
different lots of plasma and are injected. 
Stability studies 
The stability of canagliflozin was determined by measuring 
concentration change in control samples overtime under set conditions. 
Freeze-thaw stability study (-80 °C) of canagliflozin was carried out by 
subjecting samples to three freeze and thaw cycles. Samples before the 
study and after study were analysed by developed method. Similarly 
stock solution stability study of canagliflozin (Stability after 6 H), Long-
term stability (-80 °C, 30days), benchtop stability study of canagliflozin 
(at ambient temperature, 6h), dry residue stability(4 °C, 48h) and Auto-
sampler stability (4 °C, 24h) of canagliflozin were carried out by 
subjecting samples to study conditions. 
RESULTS AND DISCUSSION 
Results of method validation 
The chromatography observed during the course of validation was 
acceptable and representative chromatograms of standard blank, 
HQC, MQC and LQC samples are shown in (fig. 1-4). 
 
 
Fig. 1: Representative blank chromatograms of canagliflozin and IS in blank plasma 
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Fig. 2: Representative HQC-chromatograms of canagliflozin in plasma with internal standard 
 
 
Fig. 3: Representative MQC-chromatograms of canagliflozin and its internal standard 
 
 
Fig. 4: Representative chromatograms of canagliflozin and its internal standard at LQC Level 
 
 
Fig. 5: Calibration curve 
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Table 1: Summary of linearity standards for canagliflozin 
Actual conc. (ng/ml) 4 8 25 50 100 150 300 600 Slope Intercept 
1 3.95 7.73 25.02 50.9 102.7 150.33 309.5 586.5 0.983 2.493 
2 3.875 7.73 25.25 49.96 100.53 148.67 315.5 588.75 0.99 1.854 
3 3.975 7.86 25.44 49.23 98.76 147.67 307 582 0.976 1.729 
Mean 3.93 7.78 25.24 50.03 100.67 148.89 310.67 585.75 0.983 2.025 
±SD* 0.052 0.077 0.208 0.835 1.970 1.347 4.368 3.436 0.007 0.409 
%CV** 1.32 0.99 0.83 1.67 1.96 0.90 1.41 0.59   
% Accuracy 98.33 97.22 100.96 100.06 100.66 99.25 103.55 97.625   
LOD*** 1.38 
LOQ**** 4.17 
*Standard deviation, **coefficient of variation, ***limit of detection, ****limit of quantification. 
 
The method developed was validated for linearity, accuracy and 
precision, and stability as per ICH guidance [13-19]. The results of 
validating parameters are given below. 
Linearity 
The three calibration curves (peak area ratio Vs concentration) were 
linear over working range of 5ng/ml to 600ng/ml with eight-point 
calibration used for quantification by linear regression (fig 5 and 
table 1). The regression equation for the analysis was 0.983x-
2.025with coefficient of correction (r2) = 0.999. 
Recovery 
The % mean recovery for canagliflozin in LQC (10 ng/ml), MQC(300 
ng/ml) and HQC (500ng/ml) was 95.83%, 103.97% and 106.35% 
respectively (table 2). 
Intraday and inter-day precision 
The mean intraday and inter-day precision of the method was found 
to be 0.77 to 3.72% for the quality control samples. This is within 
the acceptance limits of precision is 15% (table 3). 
 
Table 2: The % mean recovery of canagliflozin for LQC, MQC and HQC 

















  (area ratio) (area ratio) (area ratio) (area ratio) (area ratio) (area ratio) 
1 0.164 0.151 92.073 0.956 0.984 102.93 2.077 2.158 103.90 
2 0.161 0.146 90.683 0.97 0.992 102.27 2.117 2.16 102.03 
3 0.147 0.144 97.959 0.977 0.977 100.00 1.914 2.144 112.02 
4 0.157 0.153 97.452 0.922 0.98 106.29 2.048 2.151 105.03 
5 0.146 0.145 99.315 0.927 0.985 106.26 1.989 2.096 105.38 
6 0.163 0.159 97.546 0.932 0.989 106.12 1.973 2.166 109.78 
Mean 0.156 0.150 95.838 0.947 0.985 103.977 2.020 2.146 106.356 
±SD* 0.008 0.006 3.546 0.023 0.006 2.644 0.075 0.026 3.774 
%CV** 5.11 3.87 3.70 2.48 0.56 2.54 3.70 1.19 3.55 
*Standard deviation, **coefficient of variation. 
 
Matrix effect 
The % CV for HQC and LQC samples was observed 3.39% and 2.39% 
respectively (table 4), which are within 15% as per the acceptance 
criteria. 
Stability studies 
The Stability studies were assessed using quality control samples (HQC 
and LQC) and the %mean stability for HQC and LQC were presented 
which is within the acceptance limits of 85 to 115% (table 5).  
Pharmacokinetic studies 
The Pharmacokinetic parameter of canagliflozin was calculated 
from the plasma concentration-time curves using pk solver 
software. Also, the area under the plasma concentration-time 
curve from 0 to 24hr (AUC0-24) was calculated using trapezoidal 
rule. Canagliflozin showed Tmax of 1.58±0.2 and mean Cmax, 
AUC0→t and AUC0→α for Test formulation is 272±13.24, 
2571.20±251and 2777.43±276 respectively. The results were 
presented in table 6, table 7 and fig. 6. 
 
Table 3: Intra-day and inter-day quality control samples for canagliflozin 
QC Canagliflozin (ng/ml)(n=6) 
Intra-batch 
  
LLOQ QC LQC MQC HQC 
(5ng/ml) (10ng/ml) (300ng/ml) (600 ng/ml) 
Mean* 4.93 10.59 293.70 618.53 
SD** 0.0520416 0.33 6.04 4.79 
%CV*** 1.05 3.16 2.06 0.77 
Mean 5.183333 9.10 301.13 635.24 
SD 0.052042 0.34 6.03 7.38 
%CV 1.004019 3.72 2.00 1.16 
Mean 4.703333 10.15 295.82 620.89 
SD 0.052042 0.37 5.62 9.27 
%CV 1.106484 3.64 1.90 1.49 
Inter-batch LLOQ QC LQC MQC HQC 
  (5ng/ml) (10ng/ml) (300ng/ml) (600 ng/ml) 
Mean 4.783333 0.25 2.66 5.47 
SD 0.052042 0.00 0.08 0.08 
%CV 1.087979 3.22 3.06 1.47 
*Average of six determinations, **standard deviation, ***Coefficient of variation. 
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Table 4: Matrix effect obtained with six different lots of plasma 
QCID LQC HQC 
Actual conc. (ng/ml) 10 600 
1 11.08 612.5 
2 10.95 608.9 
3 10.5 603.3 
4 10.83 604.8 
5 11.54 586.5 
6 10.62 631.3 
Mean 10.92 607.8 
±SD* 0.37 14.55 
% CV** 3.39 2.39 
% accuracy 109.24 101.31 
*Standard deviation, **coefficient of variation 
 
Table 5: Results of stability studies 
Stability condition Nominal  Calculated concentration 
Concentration (ng/ml) Mean*±SD** % Bias 
Freeze-thaw stability 
(-80 oC) 
10 10.77±0.211 7.7 
600 594±7.86 -1 
Long-term stability 
(-80 oC, 30days) 
10 9.63±0.169 -3.7 
600 594±20.8 -1 
Autosampler Stability 
 (4 oC, 24h) 
10 9.69±0.204 -3.1 
600 591±12.0 -1.5 
Bench Top stability (6h) 10 9.22±0.411 -7.8 
600 582±6.56 -3 
Dry residue stability (4 oC, 48h) 10 9.83±0.121 -1.7 
600 591±10.4 -1.5 
Autosampler Stability  
(4 oC, 24h) 
10 9.44±0.221 5.5 
600 589±8.0 -1.833333 
N=6     
*Average of six determinations, **standard deviation 
 
Table 6: Calculated plasma concentrations in rabbits at each time point 
Time points (h)  
 
Calculated concentrations (ng/ml) 
Rabbit 1 Rabbit 2 Rabbit 3 Rabbit 4 Rabbit 5 Rabbit 6 Mean SD* 
0 0 0 0 0 0 0 0 0.00 
0.15 24 15 30 21 18 12 20 6.48 
0.25 48 54 57 36 45 54 49 7.75 
0.5 102 87 96 93 111 102 98.5 8.36 
0.75 156 174 180 174 156 168 168 10.04 
1 213 243 237 207 195 207 217 18.85 
1.5 252 288 273 261 279 267 270 12.87 
2 231 249 267 246 264 279 256 17.25 
2.5 204 225 228 210 228 243 223 14.03 
3 189 174 219 198 207 234 203.5 21.42 
4 174 162 192 186 186 201 183.5 13.74 
5 165 183 183 171 162 147 168.5 13.74 
6 156 168 171 147 141 123 151 17.97 
8 147 159 150 126 108 105 132.5 22.88 
12 138 147 135 120 99 96 122.5 21.25 
16 102 114 114 93 75 66 94 20.05 
20 27 18 24 15 18 27 21.5 5.17 
24 0 0 0 0 0 0 0 0.00 
*Standard deviation. 
 
Table 7: Calculated mean values of PK parameters for test animals 
Parameter Mean* (n=6) SD** 
Lambda_z 0.11 0.01 
t1/2 6.56 0.74 
Tmax 1.58 0.20 
Cmax 272.00 13.24 
AUC 0-t 2571.20 251.54 
AUC 0-inf_obs 2777.43 275.93 
Vz/F_obs 0.04 0.00 
Cl/F_obs 0.00 0.00 
*Average of six determinations, **standard deviation 
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Fig. 6: Plasma concentration-time profile of test animals 
 
DISCUSSION 
The established LC-MS/MS method has high selectivity, sensitivity 
and linear with least LLOQ (5ng/ml) concentration and have good % 
mean recovery (102.05%) when compared to other reported 
method for the estimation of canagliflozin metabolites from human 
plasma and another biological matrix. [11-12]. Liquid-liquid 
extraction technique was employed to reduce the interference from 
plasma. As per literature review, no LC-MS/MS method was 
available for determination of canagliflozin alone from rabit plasma, 
the validated method has great importance to determine the 
pharmacokinetic parameters of canagliflozin. 
CONCLUSION 
The bio-analytical methodology for determination of canagliflozin 
described in this manuscript is highly specific, rugged and rapid for 
therapeutic drug monitoring both for analysis of routine samples of 
a single dose or multiple dose pharmacokinetics and also for clinical 
trial samples with desired sensitivity, precision, accuracy and high 
throughput. The method involved a simple and specific sample 
preparation by liquid-liquid extraction followed by isocratic 
chromatographic separation in 2.0 min. The overall analysis time is 
promising compared to other reported procedures for canagliflozin. 
The established LLOQ is sufficiently low to conduct a 
pharmacokinetic study with any marketing formulation of 
canagliflozin in healthy rabbits. 
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